Results from studies presented at annual ASCO meeting
New Orleans, LA, May 23, 2000 - Introgen Therapeutics presented data from clinical studies on the safety, transfer and expression of RPR/INGN 201 (Adenoviral p53) in three Phase I clinical studies for the treatment of bronchioalveolar cell lung carcinoma (BAC), ovarian cancer and recurrent glioblastomas at the 36th American Society of Clinical Oncology (ASCO) Annual Meeting in New Orleans, Louisiana. These studies are the subject of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) of the US National Institutes of Health (NIH) previously announced by Introgen Therapeutics and its corporate partner for its p53 program, Aventis Pharmaceuticals.
The first report, titled "A Phase I Trial of Ad p53 for Ovarian Cancer Patients: Correlation with p53 & Anti-Adenovirus," is based on research conducted by Judith Wolf, M.D., and her colleagues at The University of Texas M. D. Anderson Cancer Center. The study was designed to determine the maximum tolerable dose of adenoviral p53, administered intraperitoneally, for ovarian cancer patients and found that the therapy is well tolerated for this patient group at the administered doses.
The second report, titled "Phase I Trial of Adenovirus p53 in Bronchioalveolar Cell Lung Carcinoma Administered by Bronchoalveolar Lavage," is based on research conducted by Samir Kubba, M.D., and colleagues at The Vanderbilt Cancer Center and The University of Wisconsin Cancer Center. This study utilized a direct administration to the lower airways. Symptomatic improvement and improved lung function was reported in some patients.
The third report, titled "Preliminary Results of a Phase I Clinical Trial Of Adenovirus-Mediated p53 Gene Therapy for Recurrent Gliomas: Biological Studies," is based on research conducted by Frederick F. Lang, Assistant Professor of Neurosurgery, and colleagues at The U
Contact: Lora Pike